Cost-effectiveness of antiemetics use during cancer chemotherapy

References

• Coates A, Abraham S, Kaye SB eta]. On the receiving end: patient perception of the side effects of cancer chemotherapy. Eur Cancer Clin. Oncol 19(2), 203–208 (1983).
   Google Scholar
• Navari RM, Reinhardt RR, Gralla RJ et al Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl. Med. 340(3), 190–195 (1999).
   Google Scholar
• Hesketh PJ. Potential role of the NK1 receptor antagonist in chemotherapy-induced nausea and vomiting. Support Cate Cancer 9(5), 350–354 (2001).
   Google Scholar
• Gralla RJ. New agents, new treatment and antiemetic therapy. Semin. Oncol29(1Suppl. 4), 119–124 (2001).
   Google Scholar
• Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 18 (2), 163–173 (2000).
   Google Scholar
• •Presents a very good review of the serotonin anatgonists in chemotherapy-induced nausea and vomiting.
   Google Scholar
• Jones AL, Hill AS, Soukop M eta]. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338 (8765), 483–487 (1991).
   PubMedGoogle Scholar
• O'Brien BJ, Rusthoven J, Rocchi A eta]. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CAIAJ149(3), 296–302 (1993).
   Google Scholar
• Tanneberger S, Lelli G, Martoni A, PianaE, Pannuti E The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost—benefit index).j Chemotherapy 4 (5), 326–331 (1992).
   PubMed Web of Science ®Google Scholar
• Johnson N, Bosanquet N. Cost effectiveness of 5-hydroxytryptamine3 receptor antagonists: a retrospective comparison of ondansetron and granisetron. Anticancer clrugs6 (2), 243–249 (1995).
   Google Scholar
• Stewart DJ, Dahrouge S, Coyle D, Evans WK. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. j Clin. Oncol (1),344–351 (1999).
   Google Scholar
• Ballatori E, Rolla F, Berto P et al. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. PharmacoEconomics 5(3), 227–237 (1994).
   PubMedGoogle Scholar
• Buxton MJ, O'Brien BJ. Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. Brit./. Cancer19, S64—S67 (1992).
   Google Scholar
• Marty M, Pouillart P, Scholl S eta]. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N. Engl. Merl 322(12), 816–821 (1990).
   Google Scholar
• Cox F, Hirsch J. Ondansetron: a cost- effective advance in antiemetic therapy. Oncology50(3), 186–190 (1993).
   PubMedGoogle Scholar
• Soukop M, McQuade B, Hunter E eta]. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49(4), 295–304 (1992).
   PubMedGoogle Scholar
• Cunningham D, Gore M, Davidson N, Miocevich M, Manchanda M, Wells N. The real costs of emesis-an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur j Cancer 29A(3), 303–306 (1993).
   PubMedGoogle Scholar
• Kwong WJ, Parasuraman TV. Cost- effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy. Phar Pract. Manag. Q.19(1), 28–41 (1999).
   Google Scholar
• Lachaine J, Laurier C, Langleben A, Valliant L. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. Cut. Rev Oncol Ilernatol 32(2), 105–112 (1999).
   PubMedGoogle Scholar
• Lachaine J, Laurier C. Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy. Arn. Health Syst. Pharm. 59(19), 1837–1846 (2002).
   Google Scholar
• Sands R, Roberts JT, Marsh M, Gill A. Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis. I Clin. Oncol 4(1), 67 (1992).
   Google Scholar
• Zbrozek AS, Cantor SB, Cardenas MP, Hill DR Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Ainj Hospital Pharmacy51(12), 1555–1563 (1994).
   PubMedGoogle Scholar
• Grunberg SM. Cost-effective use of antiemetics. Oncology12(3 Suppl. 4), 38–42 (1998).
   Google Scholar
• Dranitsaris G, Leung P, Ciotti R et al A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. PharmacoEconomics 19(9), 955–967 (2001).
   PubMed Web of Science ®Google Scholar
• Tejedor I, Idoate A, Jimenez M, Sierrasesumaga L, Giraldez J. Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children. Pharm. World Sci. 21(2), 60–68 (1999).
   Google Scholar
• Barrajon E, de las PR. Randomised double-blind crossover study comparing ondansetron, granisetron and tropisetron. A cost—benefit analysis. Support Cate Cancer 8(4), 323–333 (2000).
   PubMedGoogle Scholar
• Becker AJ, Mutnick AH, Ross MB, Stilwell AA, Riggs CE, Hanson DB. Combining a clinical trial with decision analysis to evaluate antiemetic agents. Formulary 31(August), 670–683 (1996).
   Google Scholar
• Holdsworth MT, Adams VR, Raisch DW, Wood JG, Winter SS. Computerized system for outcomes-based antiemetic therapy in children. Ann. Pharmacotherapy 34(10), 1101–1108 (2000).
   Google Scholar
• Bonneterre J, Hecquet B. Granisetron (intravenous) compared with ondansetron (intravenous plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study. Bull Cancer 82(12), 1038–1043 (1995).
   PubMedGoogle Scholar
• Noble A, Bremer K, Goedhals L, Cupissol D, Dilly SG. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5 day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group. Eur. j Cancer 30A(8), 1083–1088 (1994).
   Google Scholar
• Zeidman A, Bendayan D, Benzion T, Kaufman 0, Cohen AM, Mittelman M. Granisetron and ondansetron for chemotherapy-related nausea and vomiting. Haematologia 29(1), 25–31 (1998).
   Google Scholar
• Gralla RJ, Osoba D, Kris MG etal. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. Clin. Ord 17(9), 2971–2994 (1999).
   Google Scholar
• •Important paper on how to appropriately use antiemetics in chemotherapy-induced nausea and vomiting.
   Google Scholar
• Hesketh PJ, Kris MG, Grunberg SM eta]. Proposal for classifying the acute emetogenicity of cancer chemotherapy. Clin. Oncol 15(1), 103–109 (1997).
   Google Scholar
• •Interesting proposal on how to effectively estimate emetic potential of chemotherapy.
   Google Scholar
• Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann. Oncol 14(2), 291–297 (2003).
   Google Scholar
• Dranitsaris G, Burry L, Leung P. Using decision analysis modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist anti-emetics. Proceedings of 12th International Symposium: Supportive Care in Cancer Washington DC, USA (2000).
   Google Scholar
• Johnson NE, Nash DB, Carpenter CE, Sistek CJ. Ondansetron: costs and resource utilisation in a US teaching hospital setting. PharmacoEconomics 3(6), 471–481(1993).
   PubMedGoogle Scholar
• Crucitt MA, Hyman W Grote T eta]. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. Clin. Ther. 18(4), 778–788 (1996).
   Google Scholar
• Beck TM, Hesketh PJ, Madajewicz S etal Stratified, randomized, double-blind comparison of intra venous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.j Clin. Oncoll0 (12), 1969–1975 (1992).
   Google Scholar
• Hainsworth J, Harvey W, Pendergrass K etal A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. j Clin. Oncol 9(5), 721–728 (1991).
   Google Scholar
• Hesketh PJ, Murphy WK, Lester EP etal GR 38032F (GR-0507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. j Clin. Oncol 7(6), 700–705 (1989).
   Google Scholar
• Kris MG, Gralla RJ, Tyson LB eta]. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Results of consecutive trials in 255 patients. Cancer55(3), 527–534 (1985).
   Google Scholar
• Kris MG, Gralla RJ, Clark RA, Tyson LB. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. j Natl. Cancer Inst. 81(1), 42–46 (1989).
   Google Scholar
• Kris MG, Clark RA, Tyson LB, Hahne WF, Pisters KM, Gralla RJ. Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin greater or equal to 100 mg/ m2.Ainj Clin. Oncol 16(1), 77–80 (1993).
   Google Scholar
• Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl. Med. 322(12), 810–816 (1990).
   Google Scholar
• Marty M, Droz JP, Pouillart P, Paule B, Brion N, Bons J. GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. Cancer Chemother. Pharmacol 23(6), 389–391 (1989).
   Google Scholar
• Onsrud M, Moxnes A, Sollien A, Grande T, Solesvik 0. High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma. Cancer 61(12), 2429–2432 (1988).
   Google Scholar
• Roila F, Tonato M, Basurto C etal Anti- emetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat. Rep. 69(12), 1353–1357 (1985).
   Google Scholar